Clinical utility of denosumab for treatment of bone loss in men and women by Adler, Robert A & Gill, Ranjodh S
© 2011 Adler and Gill, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2011:6 119–124
Clinical Interventions in Aging Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
119
RevIew
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CIA.S14565
Clinical utility of denosumab for treatment  
of bone loss in men and women
Robert A Adler
Ranjodh S Gill
endocrinology and Metabolism, 
McGuire veterans Affairs Medical 
Center, Richmond, vA, USA
Correspondence: Robert A Adler 
McGuire veterans Affairs Medical Center, 
1201 Broad Rock Boulevard, Richmond, 
vA 23249, USA 
Tel +1 804 675 5424 
Fax +1 804 675 5425 
email robert.adler@va.gov
Abstract: While most older patients with osteoporosis are treated with antiresorptive 
  bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, such drugs 
have side effects, remain in bone for extended periods, and lead to poor adherence to chronic 
treatment. Denosumab is a humanized monoclonal antibody and antiresorptive agent that works 
by decreasing the activity of the receptor activator of nuclear factor kappa B ligand. In major 
trials in postmenopausal women, denosumab increased bone mineral density by dual energy 
x-ray absorptiometry in the spine, hip, and distal third of the radius and decreased vertebral, 
nonvertebral, and hip fractures. Denosumab is administered by subcutaneous injection every 
six months, suggesting that adherence may be improved with such therapy. In addition, phar-
macokinetic studies measuring bone turnover markers imply that the antiresorptive effect 
diminishes more quickly over time. Whether these properties will lead to fewer long-term side 
effects needs to be proven. Denosumab has also been studied in men with prostate cancer treated 
with androgen deprivation therapy. These men, at high risk for fracture, also have increases in 
spine, hip, and forearm dual energy x-ray absorptiometry, as well as fewer morphologic vertebral 
fractures on x-ray. Denosumab is approved for postmenopausal women with osteoporosis in 
the US and Europe and for men on androgen deprivation therapy in Europe.
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Introduction
Osteoporosis remains an important problem in older adults in spite of the fact that 
generally safe and effective therapies are available. Bisphosphonates, including the 
oral bisphosphonates, ie, alendronate, risedronate, and ibandronate, and intravenous 
bisphosphonates, including ibandronate and zoledronic acid, are indicated for many 
patients with osteoporosis. These drugs, while usually well tolerated, have been associ-
ated with side effects, such as osteonecrosis of the jaw,1 atrial fibrillation,2 and atypical 
fractures of the femoral shaft.3,4 In addition, oral bisphosphonates have been reported 
to be associated with an increased risk of esophageal carcinoma.5,6 While the connec-
tion between these side effects and bisphosphonates may not be fully established, and 
indeed a recent study7 from Korea suggests that atrial fibrillation may occur less often 
in patients on bisphosphonates, the incidence of side effects is quite low. Thus, one 
reason to identify alternative antiresorptive drugs for osteoporosis would be to eliminate 
or decrease side effects. The mechanism of action and pharmacokinetics of an alterna-
tive antiresorptive might also mitigate the side effects. As recently reviewed,8 studies 
of bisphosphonates have shown a decrease in fractures of 30%–50% in three-year Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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studies, but other evidence shows that some bisphosphonates 
appear safe and effective for 5–10 years. Nonetheless, the 
optimal length of bisphosphonate treatment remains to be 
established. It is interesting that while increasing age is a 
major risk factor for fracture, most bisphosphonate studies 
did not include the “old old”.
Most bisphosphonates are oral preparations, usually taken 
weekly or monthly. Because of poor gut absorption, oral 
bisphosphonates must be taken fasting with only water. Other 
medications and nutrients must be postponed for at least half 
an hour. Zoledronic acid is administered as a yearly intrave-
nous infusion. While zoledronic acid is convenient, some 
patients will have an acute-phase reaction, particularly with 
the first dose. Perhaps more importantly, adherence to oral 
bisphosphonates has been poor,9–11 whereas long-term adher-
ence to intravenous bisphosphonates has yet to be determined. 
Patients must take approximately 80% of oral bisphosphonate 
doses in order to have decreased fracture risk.12,13 For the 
elderly patient with a heavy pill burden, the extra work 
involved with oral bisphosphonate ingestion may lead to 
poor adherence. Therefore, alternative antiresorptives that 
are more likely to result in better treatment persistence are 
very appealing.
Denosumab is a humanized monoclonal antibody 
directed against the receptor activator of nuclear factor 
kappa B ligand (RANKL).14 Normally, RANKL is produced 
by osteoblasts and acts through the receptor activator of 
nuclear factor kappa B (RANK) found on osteoclasts and 
preosteoclasts.15 RANKL interacts with RANK to stimulate 
activation of osteoclasts, leading to augmented bone 
resorption.16 Interestingly, there is a decoy receptor, known 
as osteoprotegerin, that prevents RANKL from interacting 
with RANK, thus leading to less osteoclast activation.17 
In some clinical situations, such as postmenopausal osteo-
porosis, the relation of RANKL to osteoprotegerin is such 
that osteoclast activity increases, leading to bone loss.18 
  Denosumab acts like osteoprotegerin, diminishing osteo-
clast activity.19 Unlike bisphosphonates, denosumab does 
not become incorporated into bone, yielding a much shorter 
terminal half-life.20 Therefore, denosumab presents a poten-
tial advantage and a potential disadvantage. For the patient 
who has a side effect from therapy, denosumab will be no 
longer active six months after the last dose. On the other 
hand, if patients are not receiving denosumab regularly, the 
patient’s fracture risk might increase after the dose “wears 
off”. The ramifications of this property and some specific 
examples are discussed in the following.
Denosumab in women with 
postmenopausal osteoporosis
Postmenopausal osteoporosis is the most common type of 
osteoporosis, resulting in the largest number of fractures each 
year. As the population ages, the number of fractures is pre-
dicted to rise dramatically.21 In addition to the pain, decreased 
mobility, and cost, hip fractures, and to a lesser extent verte-
bral fractures, lead to increased mortality in women and 
men.22,23 Hence, treatments that decrease fracture risk improve 
and extend the lives of patients at risk. As stated earlier, 
antiresorptive bisphosphonates have been the most commonly 
used medications in patients with osteoporosis. Bisphosphonates 
decrease fracture risk by about 40%–50% over the short term 
(three years or so). While there is controversy about whether 
the various bisphosphonates differ in their effectiveness, there 
are no head-to-head studies that demonstrate better fracture 
risk reduction by a given bisphosphonate.24,25 For this reason, 
weekly generic alendronate is usually the first treatment of 
choice because of its low cost. On the other hand, there is 
some evidence that a monthly bisphosphonate preparation or 
an annual intravenous preparation may improve persistence 
with therapy. Denosumab has the potential to improve adher-
ence to therapy because it is administered as a subcutaneous 
injection every six months, thus not adding to the pill burden 
of older patients.
Denosumab has been tested in four Phase III studies in 
postmenopausal women. The registration trial called FREE-
DOM (Fracture Reduction Evaluation of Denosumab in 
Osteoporosis Every 6 Months) is the largest and most impor-
tant. In this trial, almost 8000 women were randomized to 
receive either denosumab 60 mg or placebo by subcutaneous 
injection every six months for three years.26 To be included 
in the study, women aged 60–90 years had to have a bone 
density T score , −2.5 in the lumbar spine or total hip. 
Exclusion criteria included a T score , −4, one severe or 
two moderate prevalent fractures on spine x-ray, or recent 
exposure to oral glucocorticoids or hormone replacement 
therapy. All subjects received calcium and vitamin D 
supplements. The primary outcome was a new vertebral 
fracture diagnosed by spine x-ray. At three years, 2.3% of 
the women in the active drug group had a new vertebral 
fracture compared with 7.2% of placebo subjects. This was 
a statistically significant 68% relative risk reduction and an 
almost 5% absolute risk reduction. Clinical vertebral frac-
tures were reduced to approximately the same extent. 
Nonvertebral fractures were also reduced, ie, by 6.5% versus 
8.0%, P = 0.01). The time to first hip fracture was Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
Denosumab for bone loss
significantly shorter in the placebo group. Bone mineral 
density increased relative to the placebo group by 9.2% 
(spine) and 6% (total hip). Bone turnover markers reflecting 
both osteoclastic and osteoblastic activity were suppressed 
by denosumab compared with placebo. Adverse events 
included local injection site reactions (0.8% denosumab, 
0.7% placebo), eczema (3% denosumab, 1.7% placebo, 
P , 0.001), and cellulitis (0.3% denosumab, ,0.1% placebo, 
P = 0.002). No cases of osteonecrosis of the jaw were found, 
and the overall rates of infection and cancer as adverse events 
were the same in the active drug and placebo groups.26
A recent post hoc analysis of the FREEDOM trial evaluated 
fracture incidence in women with known risk factors for frac-
tures, including multiple and/or moderate or severe prevalent 
vertebral fractures, age 75 years or older, and/or having a 
femoral neck bone mineral density T score # −2.5.27 Compared 
with placebo, denosumab significantly reduced the risk of new 
vertebral fractures in women with multiple and/or severe ver-
tebral fractures (7.5% denosumab versus 16.6% placebo, 
P , 0.001). Similarly, denosumab significantly reduced the 
risk of hip fractures in subjects aged 75 years or older (0.9% 
denosumab versus 2.3% placebo, P , 0.01) or with a baseline 
femoral neck bone mineral density T score # −2.5 (1.4% 
denosumab versus 2.8% placebo, P = 0.02). These risk reduc-
tions in higher-risk individuals were consistent with those seen 
in patients at lower risk of fracture.
Osteoporosis is a chronic disorder, and most experts 
recommend at least five years of bisphosphonate treatment, 
based on relatively limited data.8,28 The pivotal fracture trial 
for denosumab described earlier is being followed by a 
longer-term extension study. In the meantime, there are now 
some data on up to six years of denosumab treatment. In an 
extension of a Phase II study, some postmenopausal women 
have been treated with continuous denosumab or have started 
denosumab after 1–4 years of placebo treatment (with some 
subjects having received some years of denosumab or alen-
dronate therapy).29 From the relatively small number of 
subjects studied, it can be concluded that continuous deno-
sumab leads to further gains of bone mineral density (lumbar 
spine 2.9%, total hip 1.1%, femoral neck 1.2%, distal third 
of radius 1% over the two-year extension).29 Bone resorption 
markers continued to be at about half the level at the original 
baseline. Without a full placebo group for the two-year 
extension it is difficult to determine the importance of the 
adverse events reported. Upper respiratory infections, arth-
ralgias, and back pain were the most common adverse events 
reported during the extension.
Another study compared the bone density changes over 
one year in postmenopausal women randomized to deno-
sumab or alendronate.30 At baseline, the women had a T score 
at the spine or total hip #−2. Women receiving denosumab 
had increased bone density at the total hip, femoral neck, 
lumbar spine, and distal third of radius of 3.5%, 2.4%, 5.3%, 
and 1.1%, respectively, all significantly greater than the 
changes measured in the women on weekly alendronate 
(2.6%, 1.8%, 4.2%, and 0.6%, respectively). There were no 
differences in adverse events between the two treatment 
groups, although this was only a one-year study with approxi-
mately 1200 participants. There is controversy over whether 
a greater improvement in bone density translates into a 
greater decrease in fracture risk.31,32 Nonetheless, the robust 
increase in bone density by denosumab and the fracture 
decrease reported in the registration trial strengthen the 
conclusion that denosumab is efficacious.
Denosumab in androgen 
deprivation therapy
Prostate cancer is very common in aging men, and androgen 
deprivation therapy (ADT) is used in many cases. A man 
with localized prostate cancer on ADT is at great risk for 
fracture, as high as 20% over five years, despite having a 
good overall survival outlook.33–35 Hip fracture in older men 
has particularly severe consequences. Men aged 75–84 years 
have a one in three chance of dying by one year after a hip 
fracture.36 Thus, treatment of older men on ADT might lead 
to both decreased fracture risk and decreased mortality. 
Bisphosphonates have been used successfully in men on 
ADT, but the same potential problems of adherence to 
therapy may actually be exaggerated in men on ADT.37 
After all, they have a cancer, and are affected by the other 
side effects of ADT.38 Treatment of osteoporosis in such men 
has no impact on how they feel, unless the treatment prevents 
a fracture. Convincing a man on ADT to be concerned about 
his bones is challenging, and persistence in taking a weekly 
or even monthly oral bisphosphonate will likely not be good. 
While yearly intravenous zoledronic acid works well in such 
patients, denosumab is also attractive because it can be given 
subcutaneously at every other administration of ADT ther-
apy, which is usually a gonadotropin hormone-releasing 
hormone analog provided every three months.39,40 In a study 
of about 1400 men on ADT, denosumab increased bone 
density at the spine, hip, and forearm over three years.41 
At two years, ie, the primary analysis endpoint, denosumab 
increased lumbar spine density by 5.6% compared with a Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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loss of 1% in the placebo group. This 6.7% difference 
between the active drug and placebo was similar in the total 
hip (4.8% difference), femoral neck (3.9%), and distal third 
of radius (5.5%). The difference in the distal third of radius 
is of particular interest because loss of forearm bone density 
is common in men on ADT.42 There has been one small study 
of treatment with denosumab in men with primary osteopo-
rosis, the results of which have not been published yet.
Place of denosumab in  
osteoporosis treatment
Approved uses
Denosumab appears to have some potential benefits, only 
some of which have been studied. First, it is given as a sub-
cutaneous injection in a physician’s office. Thus, for the 
approved use in postmenopausal women in the US and 
Europe, it is an attractive drug that might lead to better adher-
ence to therapy. In a study of women treated with denosumab 
for two years, three months after discontinuation of therapy 
there was a rise of bone turnover markers above the baseline.43 
It is likely that to continue the therapeutic effect would 
require the patient to return to the clinician’s office for 
another injection every six months. However, even two years 
after discontinuation of denosumab, bone mineral density 
was still higher than in placebo-treated patients.
In Europe, denosumab is approved for men on ADT for 
prostate cancer. For this indication, the drug is attractive 
because most of the men on ADT are returning to clinicians’ 
offices to receive gonadotropin hormone-releasing hormone 
analog treatment every three months. Hence, treatment of 
their osteoporosis risk can conveniently be done by deno-
sumab injection every other visit.
Unapproved uses
The following scenarios are potential uses for denosumab. 
These are not approved by government agencies, but might 
be considered for specific patients. For example, a young 
woman with asthma requiring glucocorticoids and already 
having suffered a fragility fracture is at high risk for another 
fracture.44 While bisphosphonates are used commonly in 
glucocorticoid-induced osteoporosis, a woman who retains 
reproductive potential should generally avoid bisphospho-
nates because they stay in the skeleton, are recirculated, and 
their effect on the fetal skeleton is unknown. Teriparatide 
might be considered because it does not linger in the skeleton 
after treatment.45 Denosumab might also be considered in this 
situation as well. There is only minimal evidence that deno-
sumab works in glucocorticoid-induced osteoporosis, but it 
is likely that there will be more studies.46 Another potential 
patient is a man who has had an allergic reaction to bisphos-
phonates and is not a candidate for teriparatide. Some patients 
refuse to take a daily subcutaneous injection. Others may have 
a contraindication to teriparatide, such as a history of radiation 
to bone. There are a few patients who have had severe acute-
phase reactions to intravenous zoledronic acid and may refuse 
another infusion. For such patients, offlabel use of denosumab 
might be considered. It is hoped that more studies of deno-
sumab will be published, so that there will be guidance for 
the clinician faced with a patient who does not fit into the 
categories of those studied so far.
Side effects of denosumab
As stated earlier, the side effect profile of denosumab has 
been encouraging from the major published studies. However, 
the same could be said for the early bisphosphonate trials, 
and many side effects were only noted after thousands of 
patients had used bisphosphonates. For example, the original 
studies of alendronate did not identify any patients with 
osteonecrosis of the jaw, but of course this has become a well 
known if unusual side effect. In the registration trial of 
denosumab, osteonecrosis of the jaw was not seen, but it has 
been reported in osteoporosis patients.26 In addition, deno-
sumab has been used to decrease skeletal events in patients 
with metastatic cancers, and osteonecrosis of the jaw has 
been reported more commonly in a similar proportion of 
patients as with zoledronic acid.47 Hence, we can expect that 
as many more osteoporosis patients are treated with deno-
sumab, there will be more reports of osteonecrosis of the 
jaw. The incidence will need to be assessed in comparison 
with that of other antiresorptive agents. Eczema was noted 
to occur more frequently in the denosumab subjects (3%) 
compared with placebo subjects (1.7%) in the pivotal fracture 
trial.26 Cellulitis was also more common in subjects receiving 
denosumab (0.3% versus 0.1%).26 In other Phase III studies, 
infections and neoplasms reported as adverse events were 
about the same in the active drug and placebo groups. 
Esophageal carcinoma, which may or may not be associated 
with oral bisphosphonates, is unlikely to be a problem 
because denosumab is not an oral medication. Atypical 
fractures of the femoral shaft have been more recently 
reported in patients taking long-term bisphosphonates for 
osteoporosis.3,4 While the mechanism of these fractures, the 
true incidence, and specific patient susceptibility to them 
have not been established, it is possible that such atypical 
fractures will also be found in patients taking long-term 
denosumab. As with any new medication, postmarketing Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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surveillance will be important to determine if there are any 
unexpected side effects.
Conclusion
Denosumab is potentially a very useful medication for osteo-
porosis because of the convenience of receiving a subcutane-
ous injection every six months. It appears to be well tolerated 
overall, and may be more potent than bisphosphonates, but 
longer-term studies will be necessary to determine long-term 
safety. Efficacy in the registration trial is impressive, and 
short-term safety appears to be acceptable. The long-term 
effect on bone and fracture risk requires continued vigilance. 
In addition, long-term studies will be needed to show that 
the apparent convenience of subcutaneous injection every 
six months leads to better treatment persistence than present 
bisphosphonate use.
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